Absorption of Direct Oral Anticoagulants in Cancer Patients after Gastrectomy
暂无分享,去创建一个
[1] P. Sandset,et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation , 2021, Journal of thrombosis and haemostasis : JTH.
[2] S. Thurner,et al. Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis. , 2021, European heart journal.
[3] Lara A. Kahale,et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. , 2021, Blood advances.
[4] R. Babor,et al. Evidence of impaired dabigatran absorption following laparoscopic Roux‐en‐Y gastric bypass surgery: the Auckland regional experience (2011–2018) , 2020, British journal of haematology.
[5] A. Torbicki,et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. , 2020, The New England journal of medicine.
[6] S. Noble,et al. Anticoagulation of cancer patients with non‐valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH , 2019, Journal of thrombosis and haemostasis : JTH.
[7] G. Raskob,et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism , 2019, Journal of Vascular Surgery: Venous and Lymphatic Disorders.
[8] Wonkyung Byon,et al. Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review , 2019, Clinical Pharmacokinetics.
[9] H. Versteeg,et al. Atrial fibrillation and cancer - An unexplored field in cardiovascular oncology. , 2019, Blood reviews.
[10] R. Souza,et al. Cancer-associated thrombosis: the when, how and why , 2019, European Respiratory Review.
[11] L. Alberio,et al. The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study. , 2018, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.
[12] P. Galajda,et al. How to proceed with long-term anticoagulation in patient after total gastrectomy and atrial fibrillation? , 2018, European Journal of Clinical Pharmacology.
[13] P. Metharom,et al. Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment , 2018, Cancers.
[14] G. Lyman,et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Kitchen,et al. International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants , 2018, Thrombosis and Haemostasis.
[16] W. Ageno,et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians , 2018, Journal of thrombosis and haemostasis : JTH.
[17] A. Rottenstreich,et al. The effect of bariatric surgery on direct-acting oral anticoagulant drug levels. , 2017, Thrombosis research.
[18] E. Weledji. The principles of the surgical management of gastric cancer , 2017, International journal of surgery. Oncology.
[19] Craig R. Lee,et al. Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance. , 2017, The American journal of medicine.
[20] N. Al-Sanea,et al. Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs) , 2017, Journal of Thrombosis and Thrombolysis.
[21] I. Wilding,et al. Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule , 2015, Journal of clinical pharmacology.
[22] S. Yusuf,et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). , 2014, Journal of the American College of Cardiology.
[23] I. Uraizee,et al. Novel oral anticoagulants after gastric bypass surgery: Caveat emptor , 2014 .
[24] Z. DeFilipp,et al. Subtherapeutic anticoagulation with dabigatran following Roux-en-Y gastric bypass surgery. , 2013, Journal of cardiology cases.
[25] J. Beyer-Westendorf,et al. Pharmacokinetics of rivaroxaban after bariatric surgery: a case report , 2013, Journal of Thrombosis and Thrombolysis.
[26] A. Clemens,et al. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[27] A A Rimm,et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. , 1999, Medicine.
[28] J. Samet,et al. Food and Drug Administration , 2007, BMJ : British Medical Journal.